ABBOTT PARK, Ill., Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.
A live webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
| Last Trade: | US$115.93 |
| Daily Change: | -1.20 -1.02 |
| Daily Volume: | 5,021,882 |
| Market Cap: | US$200.560B |
October 24, 2024 October 16, 2024 October 10, 2024 September 05, 2024 September 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
